These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 26265556)

  • 21. Effect of early conversion to everolimus together with prophylaxis with valganciclovir in the prevention of cytomegalovirus infection in heart transplant recipients.
    Díaz Molina B; Velasco Alonso E; Lambert Rodríguez JL; Rodríguez Bernardo MJ; Rozado Castaño J; Padrón Encalada R; Martín Fernández M; Pun Chinchai F; Colunga Blanco S; García Campos A
    Transplant Proc; 2015; 47(1):130-1. PubMed ID: 25645790
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs.
    Flechner SM; Goldfarb D; Solez K; Modlin CS; Mastroianni B; Savas K; Babineau D; Kurian S; Salomon D; Novick AC; Cook DJ
    Transplantation; 2007 Apr; 83(7):883-92. PubMed ID: 17460558
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preemptive therapy versus universal prophylaxis with ganciclovir for cytomegalovirus in solid organ transplant recipients.
    Singh N
    Clin Infect Dis; 2001 Mar; 32(5):742-51. PubMed ID: 11229841
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of cytomegalovirus prophylaxis on rejection following orthotopic liver transplantation.
    Slifkin M; Ruthazer R; Freeman R; Bloom J; Fitzmaurice S; Fairchild R; Angelis M; Cooper J; Barefoot L; Rohrer R; Snydman DR
    Liver Transpl; 2005 Dec; 11(12):1597-602. PubMed ID: 16315314
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cytomegalovirus disease after liver transplantation: diagnostics and therapy.
    Wiens M; Schmidt CA; Lohmann R; Oettle H; Blumhardt G; Neuhaus P
    Transplant Proc; 1993 Aug; 25(4):2673-4. PubMed ID: 8395108
    [No Abstract]   [Full Text] [Related]  

  • 26. Controversies in lung transplantation: management of cytomegalovirus infections.
    Zamora MR
    J Heart Lung Transplant; 2002 Aug; 21(8):841-9. PubMed ID: 12163083
    [No Abstract]   [Full Text] [Related]  

  • 27. Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients?
    Jain A; Orloff M; Kashyap R; Lansing K; Betts R; Mohanka R; Menegus M; Ryan C; Bozorgzadeh A
    Transplant Proc; 2005 Sep; 37(7):3182-6. PubMed ID: 16213344
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis.
    Rubin RH; Kemmerly SA; Conti D; Doran M; Murray BM; Neylan JF; Pappas C; Pitts D; Avery R; Pavlakis M; Del Busto R; DeNofrio D; Blumberg EA; Schoenfeld DA; Donohue T; Fisher SA; Fishman JA
    Transpl Infect Dis; 2000 Sep; 2(3):112-7. PubMed ID: 11429021
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cytomegalovirus prophylaxis with valganciclovir in kidney, pancreas-kidney, and pancreas transplantation.
    Ciancio G; Burke GW; Mattiazzi A; Leibovici Z; Dowdy L; Roth D; Kupin W; Rosen A; Jorge D; Cirocco RE; Miller J
    Clin Transplant; 2004 Aug; 18(4):402-6. PubMed ID: 15233817
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A hybrid strategy for the prevention of cytomegalovirus-related complications in pediatric liver transplantation recipients.
    Madan RP; Campbell AL; Shust GF; Kahn AR; Wistinghausen B; Posada R; Kerkar N; Shneider BL; Emre S; Herold BC
    Transplantation; 2009 May; 87(9):1318-24. PubMed ID: 19424031
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reassessing the impact of cytomegalovirus infection in kidney and kidney-pancreas transplantation.
    Becker BN; Becker YT; Leverson GE; Simmons WD; Sollinger HW; Pirsch JD
    Am J Kidney Dis; 2002 May; 39(5):1088-95. PubMed ID: 11979354
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Editorial commentary: Use of valganciclovir for prevention and treatment of cytomegalovirus disease.
    Snydman DR
    Clin Infect Dis; 2008 Jan; 46(1):28-9. PubMed ID: 18171209
    [No Abstract]   [Full Text] [Related]  

  • 33. Effective strategies to prevent cytomegalovirus disease after renal transplantation.
    Chapman JR
    Transplant Proc; 2000 Nov; 32(7):1508-9. PubMed ID: 11119809
    [No Abstract]   [Full Text] [Related]  

  • 34. A short-term preemptive treatment for cytomegalovirus infection in seropositive patients after liver transplantation.
    Dahiya D; Lee CF; Chan KM; Wu TJ; Chou HS; Cheng SS; Lee WC
    J Hepatobiliary Pancreat Sci; 2011 Jan; 18(1):32-8. PubMed ID: 20499109
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ganciclovir for cytomegalovirus infection in renal transplant recipients.
    Lancet; 1989 Jan; 1(8631):216-7. PubMed ID: 2563118
    [No Abstract]   [Full Text] [Related]  

  • 36. Cytomegalovirus prophylaxis by ganciclovir followed by high-dose acyclovir in renal transplantation: a randomized, controlled trial.
    Pouteil-Noble C; Megas F; Chapuis F; Bosshard S; Colin C; Hadj-Aissa A; Pozet N; Martin X; Lefrançois N; Garnier JL; Aymard M; Touraine JL
    Transplant Proc; 1996 Oct; 28(5):2811. PubMed ID: 8908072
    [No Abstract]   [Full Text] [Related]  

  • 37. Cytomegalovirus infection in kidney transplantation: prophylaxis and management.
    Bulinski P; Toledo-Pereyra LH; Dalal S; Hernandez G
    Transplant Proc; 1996 Dec; 28(6):3310-1. PubMed ID: 8962286
    [No Abstract]   [Full Text] [Related]  

  • 38. Cytomegalovirus prevention strategies: the case for prophylaxis.
    Snydman DR
    Am J Transplant; 2009 May; 9(5):1254. PubMed ID: 19422353
    [No Abstract]   [Full Text] [Related]  

  • 39. Delayed-onset primary cytomegalovirus disease after liver transplantation.
    Arthurs SK; Eid AJ; Pedersen RA; Dierkhising RA; Kremers WK; Patel R; Razonable RR
    Liver Transpl; 2007 Dec; 13(12):1703-9. PubMed ID: 18044717
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients.
    Nashan B; Gaston R; Emery V; Säemann MD; Mueller NJ; Couzi L; Dantal J; Shihab F; Mulgaonkar S; Seun Kim Y; Brennan DC
    Transplantation; 2012 Jun; 93(11):1075-85. PubMed ID: 22683823
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.